Farallon Capital Management LLC Ikena Oncology, Inc. Transaction History

Farallon Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$3.23 - $7.4 $1.62 Million - $3.72 Million	-502,077 Reduced 63.39%	290,000 $1.29 Million
Q1 2022 May 16, 2022	SELL	$5.61 - $13.85 $1.62 Million - $4.01 Million	-289,232 Reduced 26.75%	792,077 $4.83 Million
Q4 2021 Feb 14, 2022	SELL	$10.52 - $16.96 $379,140 - $611,238	-36,040 Reduced 3.23%	1,081,309 $13.6 Million
Q2 2021 Aug 13, 2021	SELL	$13.27 - $26.0 $3.08 Million - $6.04 Million	-232,164 Reduced 17.2%	1,117,349 $15.7 Million
Q1 2021 May 17, 2021	BUY	$25.6 - $32.0 $34.5 Million - $43.2 Million	1,349,513 New	1,349,513 $38.1 Million

30.6M

Ticker IKNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,257,500
Market Cap $56.9M
Description
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. I...

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Farallon Capital Management LLC with notifications on news.